Lucia R I Millham1, Justine A Scott1, Paul E Sax2, Fatma M Shebl1, Krishna P Reddy1,3,4, Elena Losina4,5,6, Rochelle P Walensky1,2,4,7,8,9, Kenneth A Freedberg1,4,7,8,9,10. 1. Department of Medicine, Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA. 2. Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA. 3. Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA. 4. Harvard Medical School, Boston, MA. 5. Department of Orthopedic Surgery, Brigham and Women's Hospital, Boston, MA. 6. Department of Biostatistics, Boston University School of Public Health, Boston, MA. 7. Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA. 8. Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA. 9. Harvard University Center for AIDS Research, Cambridge, MA; and. 10. Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, MA.
Abstract
BACKGROUND: We projected the clinical outcomes, cost-effectiveness, and budget impact of ibalizumab plus an optimized background regimen (OBR) for people with multidrug-resistant (MDR) HIV in the United States. METHODS: Using the Cost-Effectiveness of Preventing AIDS Complications microsimulation model and a health care sector perspective, we compared 2 treatment strategies for MDR HIV: (1) IBA + OBR-ibalizumab plus OBR and (2) OBR-OBR alone. Ibalizumab efficacy and cohort characteristics were from trial data: mean age 49 years, 85% male, and mean CD4 150/µL. Six-month viral suppression was 50% with IBA + OBR and 0% with OBR. The ibalizumab loading dose cost $10,500, and subsequent ibalizumab injections cost $8400/month; OBR cost $4500/month. Incremental cost-effectiveness ratios (ICERs) were calculated using discounted (3%/year) quality-adjusted life years (QALYs) and costs. ICERs ≤$100,000/QALY were considered cost-effective. We performed sensitivity analysis on key parameters and examined budget impact. RESULTS: In the base case, 5-year survival increased from 38% with OBR to 47% with IBA + OBR. Lifetime costs were $301,700/person with OBR and $661,800/person with IBA + OBR; the ICER for IBA + OBR compared with OBR was $260,900/QALY. IBA + OBR was not cost-effective even with 100% efficacy. IBA + OBR became cost-effective at base case efficacy if ibalizumab cost was reduced by ≥88%. For an estimated 12,000 people with MDR HIV in the United States, IBA + OBR increased care costs by $1.8 billion (1.5% of total treatment budget) over 5 years. CONCLUSIONS: For people with MDR HIV lacking other treatment options, ibalizumab will substantially increase survival when effective. Although adding ibalizumab to OBR is not cost-effective, the low number of eligible patients in the United States makes the budget impact relatively small.
BACKGROUND: We projected the clinical outcomes, cost-effectiveness, and budget impact of ibalizumab plus an optimized background regimen (OBR) for people with multidrug-resistant (MDR) HIV in the United States. METHODS: Using the Cost-Effectiveness of Preventing AIDS Complications microsimulation model and a health care sector perspective, we compared 2 treatment strategies for MDR HIV: (1) IBA + OBR-ibalizumab plus OBR and (2) OBR-OBR alone. Ibalizumab efficacy and cohort characteristics were from trial data: mean age 49 years, 85% male, and mean CD4 150/µL. Six-month viral suppression was 50% with IBA + OBR and 0% with OBR. The ibalizumab loading dose cost $10,500, and subsequent ibalizumab injections cost $8400/month; OBR cost $4500/month. Incremental cost-effectiveness ratios (ICERs) were calculated using discounted (3%/year) quality-adjusted life years (QALYs) and costs. ICERs ≤$100,000/QALY were considered cost-effective. We performed sensitivity analysis on key parameters and examined budget impact. RESULTS: In the base case, 5-year survival increased from 38% with OBR to 47% with IBA + OBR. Lifetime costs were $301,700/person with OBR and $661,800/person with IBA + OBR; the ICER for IBA + OBR compared with OBR was $260,900/QALY. IBA + OBR was not cost-effective even with 100% efficacy. IBA + OBR became cost-effective at base case efficacy if ibalizumab cost was reduced by ≥88%. For an estimated 12,000 people with MDR HIV in the United States, IBA + OBR increased care costs by $1.8 billion (1.5% of total treatment budget) over 5 years. CONCLUSIONS: For people with MDR HIV lacking other treatment options, ibalizumab will substantially increase survival when effective. Although adding ibalizumab to OBR is not cost-effective, the low number of eligible patients in the United States makes the budget impact relatively small.
Authors: Eric L Ross; Milton C Weinstein; Bruce R Schackman; Paul E Sax; A David Paltiel; Rochelle P Walensky; Kenneth A Freedberg; Elena Losina Journal: Clin Infect Dis Date: 2015-01-12 Impact factor: 9.079
Authors: Kathryn R Tringale; Kate T Carroll; Kaveh Zakeri; Assuntina G Sacco; Linda Barnachea; James D Murphy Journal: J Natl Cancer Inst Date: 2018-05-01 Impact factor: 13.506
Authors: Dhruv S Kazi; Joanne Penko; Pamela G Coxson; Andrew E Moran; Daniel A Ollendorf; Jeffrey A Tice; Kirsten Bibbins-Domingo Journal: JAMA Date: 2017-08-22 Impact factor: 56.272
Authors: Douglas D Richman; Sally C Morton; Terri Wrin; Nicholas Hellmann; Sandra Berry; Martin F Shapiro; Samuel A Bozzette Journal: AIDS Date: 2004-07-02 Impact factor: 4.177
Authors: Agnes C Paquet; Owen D Solberg; Laura A Napolitano; Joseph M Volpe; Charles Walworth; Jeannette M Whitcomb; Christos J Petropoulos; Mojgan Haddad Journal: Antivir Ther Date: 2014-02-12
Authors: Ethan D Borre; Emily P Hyle; A David Paltiel; Anne M Neilan; Paul E Sax; Kenneth A Freedberg; Milton C Weinstein; Rochelle P Walensky Journal: J Infect Dis Date: 2017-10-17 Impact factor: 7.759